CAPTRUST Financial Advisors’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
Other funds holding ALDX
KCM
KCM
6CM
CAPTRUST Financial Advisors's ALDX Position: Q2 2026 in Review
CAPTRUST Financial Advisors reduced its Aldeyra Therapeutics (ALDX) stake by 2.2% in Q2 2026, selling an estimated $2.01K and leaving 51,778 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #3026.
CAPTRUST Financial Advisors first reported a position in ALDX in Q4 2021 and has held it in 16 quarters since. The position peaked at $277K in Q3 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.
- CAPTRUST Financial Advisors held 51,778 shares of Aldeyra Therapeutics worth $110K as of Q2 2026.
- CAPTRUST Financial Advisors sold 1,169 Aldeyra Therapeutics shares in Q2 2026, an estimated $2.01K.
- Aldeyra Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3026 holding.
- CAPTRUST Financial Advisors first reported a position in Aldeyra Therapeutics in Q4 2021 and has held it in 16 quarters since.
- CAPTRUST Financial Advisors's Aldeyra Therapeutics position peaked at $277K in Q3 2025.
- 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.